

a). Remarks

The claims are 16, 19, 20, 35 and 42-44. In the Advisory Action mailed November 3, 2005, the Examiner noted regarding claim 16 that the carrier and derivative were encapsulated in a liposome may be deemed to be indefinite since it was alleged to be unclear if the composition has only liposomes without external medium since both are said to be encapsulated. Applicants wish to address the Examiner's concern.

Claim 16 recites a pharmaceutical composition comprising a carrier and an active ingredient wherein the carrier and active ingredient are encapsulated in a liposome. Claim 16 is open-ended and does not exclude other ingredients, carriers and the like either within or externally of the liposomes. The pharmaceutical composition can be a suspension of the liposomes as recited on page 12 and/or can be a preparation suitable for injection, for oral ingestion, as an eyedrop, as a suppository, and the like. See page 13. Further, other ingredients such as fillers or freeze-drying agents can be added as required. It is important that the active agent not leak from the liposomes to control drug delivery. Carrier is present in the liposome, but other carrier(s) can be present internally or externally as required for delivery.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Peter Saxon", written over a horizontal line.

Peter Saxon
Attorney for Applicants
Registration. No. 24,947

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

PS\ac

NY_Main 537991_1